For research use only. Not for therapeutic Use.
Ciraparantag（Cat No.:I006142）is an investigational antidote designed to reverse the anticoagulant effects of direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran. It works by binding to the anticoagulant agents, neutralizing their activity, and restoring normal blood clotting. This makes it a potential life-saving treatment in cases of bleeding complications or emergency surgeries in patients on DOACs. Ciraparantag has been evaluated in clinical trials for its safety, efficacy, and tolerability, with promising results in rapidly reversing anticoagulation, though further studies are needed to establish its widespread use.
| Catalog Number | I006142 |
| CAS Number | 1438492-26-2 (free base) |
| Synonyms | PER977; PER-977; PER 977; Aripazine; Ciraparantag;(2S,2/’S)-N,N/’-(piperazine-1,4-diylbis(propane-3,1-diyl))bis(2-amino-5-guanidinopentanamide) |
| Molecular Formula | C22H48N12O2 |
| Purity | ≥95% |
| Target | Factor Xa |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| IUPAC Name | (2S)-2-amino-N-[3-[4-[3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propyl]piperazin-1-yl]propyl]-5-(diaminomethylideneamino)pentanamide |
| InChI | InChI=1S/C22H48N12O2/c23-17(5-1-7-31-21(25)26)19(35)29-9-3-11-33-13-15-34(16-14-33)12-4-10-30-20(36)18(24)6-2-8-32-22(27)28/h17-18H,1-16,23-24H2,(H,29,35)(H,30,36)(H4,25,26,31)(H4,27,28,32)/t17-,18-/m0/s1 |
| InChIKey | HRDUUSCYRPOMSO-ROUUACIJSA-N |
| SMILES | C1CN(CCN1CCCNC(=O)[C@H](CCCN=C(N)N)N)CCCNC(=O)[C@H](CCCN=C(N)N)N |
| Reference | </br>1:Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck RJ, Costin JC.Thromb Haemost. 2017 Jan 26;117(2):238-245. doi: 10.1160/TH16-03-0224. Epub 2016 Nov 17. PMID: 27853809 </br>2:Ciraparantag for enoxaparin reversal: Adding to the evidence. Weitz JI, Eikelboom JW.Thromb Res. 2016 Oct;146:106-107. doi: 10.1016/j.thromres.2016.08.013. Epub 2016 Aug 13. No abstract available. PMID: 27544033 </br>3:Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC.Thromb Res. 2016 Oct;146:113-118. doi: 10.1016/j.thromres.2016.07.008. Epub 2016 Jul 18. PMID: 27470323 </br>4:Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Hu TY, Vaidya VR, Asirvatham SJ.Vasc Health Risk Manag. 2016 Feb 17;12:35-44. doi: 10.2147/VHRM.S89130. eCollection 2016. Review. PMID: 26937198 Free PMC Article |
